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1. Introduction 
Adult acute lymphoblastic leukemia (ALL) is characterized by a high relapse rate, with the 
majority of patients developing chemo-resistance and ultimately dying of the disease with a 
5-year survival rate of 40% (Faderl et al., 2010). Significant advances, however, have been 
made in cases carrying the acquired genetic alteration BCR-ABL (ALL-Ph+) targeted by 
tyrosine-kinase inhibitors (Ottmann & Pfeifer, 2009). Therefore, several studies have recently 
been carried out to look for additional, therapeutically exploitable, genetic lesions. Aberrant 
activation of signal transduction pathways (STP) implicated in proliferation and survival 
mechanisms are generally involved in leukemogenesis and drug resistance (Zhao et al., 
2010). Genes in the PI3K/PTEN/AKT/mTOR, RAS/RAF/MEK/ERK, and Jak/STAT 
pathways are frequently mutated and their expression is often altered in hematopoietic 
malignancies, including ALL (McCubrey et al., 2011; Steelman et al. 2008). In addition, 
deregulation of survival mechanisms may confer chemo-resistance to leukemic cells, 
particularly involving alterations of the Bcl-2 signaling cascade, which may represent one of 
the most important, potentially druggable, pathways for therapeutic intervention in ALL. 
Starting from our studies on chemo-resistance in ALL, particularly on multidrug resistance 
(MDR1) expression and prognostic significance, in this chapter we will illustrate the major 
pathways aberrantly activated in ALL -  PI3K/PTEN/AKT/mTOR, RAF/RAS/MEK/ERK, 
and the Bcl-2 family of proteins - with the ultimate goal of summarizing novel targets for 
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molecular therapies, especially in resistant/refractory cases. Controversies on and potential 
benefits of novel approaches based on STP inhibitors will be discussed. Epigenetic changes 
will be examined to address their importance in association with post-translational 
modifications. Future perspectives will encompass review of Reverse Phase Protein Arrays 
(RPPA) as a promising new tool for translational studies in clinical sample series, helping 
define the functional proteomic profile at steady-state; this approach may lead to the 
identification of aberrant molecular target(s), possibly guiding the choice of specific 
molecular therapies, on one hand, and leading to the elucidation of post-treatment changes, 
on the other, with the overall objective of improving the strategies currently employed to 
counteract leukemia chemo- and targeted drug-resistance.   
2. Multidrug resistance 
Chemo-resistance has been one of the major problems in cancer treatment, contributing to 
therapeutic failure, particularly in leukemia patients treated with regimens containing drugs 
such as anthracyclines, vinca alkaloids, or epipodophyllins, all modulated in their 
intracellular retention by the P-glycoprotein 170 (P-gp) product of the mdr-1 gene (Longley 
et al., 2005). An expanding number of proteins with a prominent role in MDR-dependent 
mechanisms of accelerated drug efflux and potentially implicated in leukemia drug 
resistance have been described: the multidrug resistance-associated protein 1 (MRP1), the 
lung-resistance protein (LRP) and the transporter breast cancer resistance protein (BCRP) 
(Chen, 2010). MRP1 is a protein distinct from MDR1, with different substrate specificity 
(amphophilic anions or glutathione-conjugated) and different susceptibility to drugs that 
can restore chemotherapy sensitivity (butathionine, which depletes intracellular glutathione 
content). LRP is a component of the major vault protein complex that appears to be involved 
in nuclear-cytoplasmic trafficking and in promoting drug redistribution away from the 
nucleus. BCRP is another member of the ATP-binding cassette protein involved in the MDR 
phenotype. In our previous studies (Tafuri et al., 2002) we have established the frequency 
and biologic–clinical significance of MDR1 expression and function and of MDR-associated 
proteins in de novo adult ALL. Our analysis was performed in the context of the ALL0496 
study of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto) cooperative 
group. This prospective multicenter study enrolled a large series of uniformly treated de 
novo adult ALL patients, providing a unique opportunity to investigate the prognostic 
influence of MDR1 on CR achievement and clinical outcome, in context with other clinical 
and biological factors. Our results indicate that MDR1 is expressed in approximately 20% of 
patients enrolled in the study, playing a statistically significant unfavorable prognostic role 
on CR achievement at both univariate and multivariate analysis; in addition, together with 
age and CD34 expression, MDR1 expression significantly predicted response failure. Since 
MDR1 expression was described as an independent predictor of CR in patients with de novo 
adult ALL, additional studies (Gregorj et al., 2005) were performed by our group to 
investigate the prognostic role of other proteins implicated in drug efflux mechanisms in 
ALL. Analysis of primary ALL samples evaluated for the expression of MRP1 and BCRP 
found these proteins expressed in 51.3% and 72.9% of the cases, respectively. BCRP 
expression was associated with age (P=0.027), but not with MDR1 expression. Neither BCRP 
nor MRP1 individually influenced CR achievement. In contrast, when their simultaneous co-
expression was analyzed, the majority of double negative patients achieved CR (P=0.034). 
Alterations in drug-efflux due to aberrant ABC transporter protein expression in cancer cells 
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led to the development of P-gp inhibitors, tested in clinical trials with discouraging results. 
In fact, the combined use of the MDR-reversal agent cyclosporine was associated with 
unacceptable toxicity, while a second generation-drug, vaslapodar (PSC-833), had 
unpredictable pharmacokinetic interactions. Third-generation inhibitors (tariquidar XR9576, 
zosuquidar LY335979, laniquidar R101933, and ONT-093) have high potency and specificity 
for P-gp but no appreciable impact on cytochrome P450 3A4 drug metabolism and no 
clinically significant drug interactions with common chemotherapy agents. Overall, the 
proposed chemo-sensitizing activity of MDR-reversal agents evaluated in clinical trials 
failed to improve either response rate or survival in leukemia patients (Molnár et al., 2010). 
Since advances in microarray and proteomic technologies, in conjunction with the 
development of novel small molecules therapeutically targeting molecular determinants of 
resistance in cancer cells, have opened new opportunities to combat chemo-resistance, 
studies have explored and characterized the signaling pathways involved in the regulation 
of tumor cell response to chemotherapy, mostly those involved in aberrant proliferation and 
prolonged survival.  
3. Signal transduction pathways 
Leukemic cells are frequently characterized by the constitutive activation of multiple 
signaling cascades, which ensures a proliferative and survival advantage over normal 
hematopoietic cells. In fact, several studies have shown that the PI3K/PTEN/AKT/mTOR, 
RAS/RAF/MEK/ERK, Notch1, and JAK/STAT pathways are frequently up-regulated in 
ALL (Brown et al., 2008). Herein, some of these key signaling are reviewed as potential 
molecular targets for specific therapeutic interventions in ALL (Fig.1). 
3.1 PI3K/PTEN/AKT/mTOR pathway 
The phosphoinositide 3-kinase (PI3K)/PTEN/AKT/mTOR pathway is a crucial signaling 
cascade involved in the control of cell growth, survival, proliferation, motility, apoptosis 
and autophagy (Fig. 1). This pathway plays a pivotal role in maintaining numerous 
physiological processes, such as nutrient uptake, ribosomal biogenesis and cellular 
metabolism (Brown et al., 2008). PI3K is activated by a variety of extracellular stimuli, 
including receptor tyrosine kinases (i.e. FLT3, EGFR, HER-2/neu) (Fathi et al., 2010). The 
activation of PI3K catalyzes the phosphatidylinositol-4,5-bisphosphate (PIP2) conversion to 
the phosphatidylinositol-3,4,5-trisphosphate (PIP3) at the inner surface of the cell 
membrane, allowing for the recruitment of PDK1 and AKT to the membrane. AKT is an 
important mediator of the intracellular cascade, acting on multiple downstream targets to 
regulate proliferation and apoptotic signals. Downstream of AKT, a key protein is 
represented by mTOR, which regulates translation in response to nutrient levels (Fig.1). The 
major negative regulator of the PI3K/AKT/mTOR pathway is the lipid phosphatase PTEN 
(Phosphatase and tensin homologue deleted on chromosome 10). 
The PI3K/PTEN/AKT/mTOR pathway is deregulated in several human cancers, including 
ALL. First, Barata et al. (2004) demonstrated that the PI3K pathway is essential for IL-7–
mediated survival, activation, proliferation, and growth of T-ALL cells indicating the 
existence of a functional IL-7–mediated PI3K signaling cascade in T-ALL cells. Additional 
reports showed that the constitutive activation of PI3K/PTEN/AKT/mTOR pathway occurs 
frequently in childhood ALL and is crucial for blast survival (Avellino et al., 2005; Jotta et 
al., 2010). Aberrant activation of this signaling cascade can be induced by overproduction of 
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growth factors or chemokines, by loss of PTEN expression, or by mutations in PTEN or in 
other mediators downstream of growth factor receptors (RAS and PI3K itself). PTEN 
mutations, deletions or inactivation are found in many ALL cell lines and are particularly 
frequent in human T-ALL cell lines derived from relapsed patients (Jotta et al., 2010). 
Conversely, PTEN gene mutations have been reported in a small but significant subset of de 
novo T-ALL patients (Silva et al., 2008). The NOTCH1 receptor, which is activated by 
mutations in about 50% of T-ALL, inhibits PTEN expression that, in turn, leads to AKT 
activation and resistance to glucocorticoids. Additionally, the PI3K/PTEN/AKT/mTOR 
pathway has been proposed to be involved in the regulation of MDR-1 expression and drug 
resistance in ALL, as suggested by cleavage of the 170-kDa P-gp during PI3K inhibitor-
induced apoptosis of VBL100 human T-lymphoblastoid CEM cells (Mantovani et al., 2006).  
All these findings lend significant support to the development of therapies targeting the 
PI3K/PTEN/AKT/mTOR pathway in ALL, particularly in T-ALL. 
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Fig. 1. PI3K/PTEN/AKT/mTOR and  RAS/RAF/MEK/ERK pathways and their sites of 
interaction.  
Inhibition of the PI3K signaling cascade can be achieved by targeting the pathway at 
different levels or simultaneously at multiple sites. In addition, however, these effects could 
be enhanced by also inhibiting crosstalking pathways. Specific inhibitors of PI3K, AKT and 
mTOR have shown significant promise in preclinical studies and are now under evaluation 
in clinical trials (Tab. 1) (Fathi et al., 2010; Levitzki & Klein, 2010; Zhao, 2010). Levy et al. 
(2009) reported that GSK690693, a pan-AKT kinase inhibitor, induces growth inhibition and  
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Table 1. PI3K/PTEN/AKT/mTOR inhibitors in hematological malignancies. 
apoptosis of most of the ALL cell lines tested (89%), and exerts a selective antiproliferative 
effect on malignant cells (lack of effects on normal human CD4+ peripheral T lymphocytes). 
Much attention has been  recently focused on blocking mTOR. This component of PI3K 
signaling cascade can form two distinct complexes termed mTORC1 and mTORC2 (Bjornsti 
& Houghton, 2004; Ciuffreda et al., 2010; Steelman et al., 2008). The first complex, composed 
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of mTOR, GβL/Mlst8, PRAS40, RAPTOR and Deptor, is sensitive to the mTOR inhibitors 
(MTIs), such as rapamycin and its analogs RAD001, CCI-779 and AP23573 (rapalogs). 
Conversely, mTORC2 complex is generated when mTOR is associated with GβL, mSIN1, 
RICTOR, and PROTOR/PRR5. Rapamycin and its analogs are in this case unable to disrupt 
mTORC2 activity. However, it has been demonstrated that prolonged exposure and/or 
higher concentrations of MTIs may inhibit mTORC2. MTIs are currently in various stages of 
development for treatment of human cancer, as they showed great preclinical promise in the 
treatment of many cancer types, including ALL (Chappell et al., 2011). A recent ongoing 
phase I/II study from Amadori et al. performed in acute myeloid leukemia (AML) by 
combining the RAD001 with clofarabine, has been preliminary reported with encouraging 
results in a poor prognosis patient population overexpressing the drug-target (Amadori et 
al., 2010). It has been reported that inhibition of mTOR by rapamicin leads to apoptosis of 
blasts from ALL patients of both B-cell and T-cell origin (Avellino et al., 2005). The efficacy 
of CCI-779 (temsirolimus) in primary human ALL was also evaluated by Teachey et al. 
(2006), who demonstrated its activity using both NOD/SCID xenograft models and bone 
marrow-derived stromal cell co-culture systems. They observed that CCI-779 induced a 
dramatic decrease in cell proliferation and an increase of apoptosis in lymphoblasts from 
adult B-ALL patients cultured on bone marrow stroma. Moreover, in a NOD/SCID 
xenograft model they found that CCI-779 showed a decrease in peripheral blood blast 
counts and in splenomegaly. More recently, Batista et al. (2011) reported that inhibition of 
mTOR by CCI-779 markedly potentiated the anti-leukemic effects of dexamethasone and 
doxorubicin in primary T-ALL cells, showing in addition highly synergistic interactions in 
combination with other specific inhibitors of the PI3K cascade or with inhibitors of JAK3 
signaling. According to the observation that ALL cells are frequently characterized by the 
deregulation of the apoptotic machinery, we explored in vitro a novel therapeutic strategy 
for ALL cells based on the combined inhibition of mTOR signaling and Bcl-2 activity, using 
CCI-779 and ABT-737, a small molecule BH3-mimetic that inhibits Bcl-2/Bcl-xL proteins 
(Iacovelli et al., 2010). We demonstrated that the simultaneous inhibition of Bcl-2 and mTOR 
pathways results in higher apoptotic effects and decreased proliferation in ALL cell lines 
and primary cells. Nevertheless, the evidence of a phenotype resistant to the ABT-737/CCI-
779 combination prompts further studies on the simultaneous interruption of multiple 
pathways in ALL. 
3.2 RAS/RAF/MEK/ERK pathway 
In the last decades, the RAS/RAF/MEK/ERK pathway (Fig. 1) has emerged as one of the 
key components of the signaling network that regulates several cellular processes, such as 
cell growth, proliferation, survival, and, under certain conditions, also differentiation, 
migration and apoptosis (Tortora et al., 2007; Steelman et al., 2011). The RAS cascade is 
activated by a large number of extracellular stimuli and various internal processes. At the 
intracellular level, through a sequential phosphorylation and activation of protein kinases, 
regulates a wide array of substrates, including transcription factors and other protein 
kinases (Steelman et al., 2011; Wang et al., 2007).  
Deregulation of RAS signaling is commonly found in cancer cells and is often caused by 
mutations in the RAS family of genes or by endogenous receptor-ligand interactions, 
resulting in a constitutive activation of G proteins. Mutations in NRAS and KRAS2 have 
been demonstrated in 15% and 22%, respectively, of childhood ALL (Case et al., 2008). A 
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persistently active form of RAS signaling can also arise from mutations in genes encoding 
others proteins that impinge on this signaling pathway and that have recently been shown 
to be mutated in childhood ALL, such as FLT3, PTPN11, and BRAF (Taketani et al., 2004; 
Tartaglia et al., 2004). By a complete mutational screen of key exons of NRAS, KRAS2, 
PTPN11, FLT3, and BRAF in a large cohort of unselected ALL cases at diagnosis and at 
relapse, Case et al. (2008) showed that somatic mutations of these genes represent a common 
genetic aberration in childhood ALL and are related to disease progression, thus providing 
the rational base for including RAS inhibitors as novel targeted therapy for childhood ALL. 
Evidences provided by our group and others, indicate that the RAS/RAF/MEK/ERK 
pathway is an extremely promising therapeutic target in hematological malignancies. 
Studies performed in ALL have shown constitutive ERK phosphorylation in 30% of clinical 
samples and higher ERK kinase activity in ALL primary cells, compared to normal BM cells 
(Meng et al., 2003; Towatari et al., 1997). During the past years, we have described the 
incidence and prognostic impact of constitutive ERK activation in a large series of ALL 
clinical samples taken at diagnosis from 131 patients uniformly treated according to the 
GIMEMA LAL 2000 study protocol (Gregorj et al., 2007). One third (34,5%) of these samples 
showed constitutive activation of ERK, as evaluated using a flow cytometric assay that 
quantifies phosphoprotein expression in individual cells. We found that constitutive ERK 
activation was associated with higher WBC counts (p=0.013); most importantly, ERK 
phosphorylation was an independent predictor of failure to achieve CR (P=0.027) in 
multivariate analysis. Consequently, strategies aimed at inhibiting MEK activity have been 
investigated experimentally. 
Potent small-molecules that selectively inhibit different molecular targets of the 
RAS/RAF/MEK/ERK pathway have been developed (Wang et al., 2007). These compounds 
have shown promising anticancer activity in vitro and in vivo by suppressing tumor growth 
and/or inducing apoptosis in a broad spectrum of solid tumors and in hematological 
malignancies including AML, multiple myeloma (MM), lymphomas and ALL. Some of them 
are currently under investigation in early-phase clinical trials (Chappell et al., 2011).   
We have investigated the molecular and functional consequences of the pharmacological 
disruption of the MEK/ERK module by selective inhibitors of MEK. However, discouraging 
preliminary results were observed in both ALL primary cells and cell lines exposed in vitro 
to the MEK inhibitors PD98059 and PD0325901, with significant inhibition of ERK 
phosphorylation in a proportion of samples, but neither occurrence of cell cycle changes nor 
induction of apoptosis (Tafuri et al, unpublished results). These data may suggest that in 
ALL pro-survival signals could be mediated by additional pathways. Nevertheless, since 
one of the most exciting features of MEK inhibitors as potential anticancer agents is their 
ability to lower cancer cells’ apoptotic threshold, sensitizing tumor cells to the proapoptotic 
action of other agents, they represent useful tools for building up pharmacological 
combinations with synergistic proapoptotic effects (Milella et al., 2005; Tortora et al., 2007). 
4. Apoptosis modulators 
In order to maintain cells homeostasis, a correct balance between cell proliferation and 
survival is preserved by several mechanisms, including the physiologic cell death program, 
called “apoptosis”. During this process, old, mutated or irreparably damaged cells are 
removed from the organism in a properly regulated fashion, without eliciting an 
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inflammatory response (Danial & Korsmeyer, 2004). In mammalian cells, apoptosis can be 
triggered by a broad variety of stimuli such as developmental signals, cellular stress or DNA 
damage, cytotoxic insults or environmental factors, resulting in activation of two different 
apoptotic signaling pathways: the extrinsic and the intrinsic pathway. The extrinsic pathway 
is activated in response to the binding of extracellular signals to cell surface death receptors 
(Ashkenazi et al., 1999) and it is independent of mitochondrial involvement. Instead, the 
intrinsic pathway is activated by intracellular events that involve the release of apoptotic 
factors from mitochondria (Danial & Korsmeyer, 2004). In particular, the intrinsic pathway 
involves a mechanism called “mitochondrial outer membrane permeabilization” (MOMP) 
by which several apoptotic factors such as cytochrome c, AIF and Smac-DIABLO, are 
released into the cytoplasm (Green & Reed, 1998; Wang et. al, 2001). MOMP following cell-
intrinsic apoptotic stimuli is to a large extent regulated by the Bcl-2 family of proteins (van 
Loo et al., 2002), which thus constitute a critical checkpoint of the intrinsic pathway. Bcl-2 
was first identified at the chromosomal breakpoint of t(14;18)-bearing human follicular B-
cell lymphoma (Tsujimoto et al., 1985) and its oncogenic potential has been demonstrated 
through a gene transfer approach (Reed et al., 1988). The Bcl-2 family is an evolutionarily-
conserved family of proteins that consists of more than 20 members which can be divided 
into three subgroups based on their function and on the presence of conserved Bcl-2 
homology (BH) regions (Fig. 2). The most important members of the Bcl-2 antiapoptotic 
repertoire contain four Bcl-2 homology domains (BH1–4) and are generally integrated 
within the outer mitochondrial membrane (OMM), including Bcl-2, Bcl-2 related gene A1 
(A1) and the long isoform Bcl-xL, Bcl-w and myeloid cell leukemia 1 (Mcl-1). Their function 
is to preserve and maintain OMM integrity by direct inhibition of the proapoptotic members 
of the family (Green & Evan, 2002). The proapoptotic proteins are divided into two groups: 
effector proteins and BH3-only proteins. The multi-region proapoptotic effector proteins, 
Bax and Bak, were conventionally thought to share BH 1–3 regions; however, by structure-
based alignment of globular Bcl-2 family proteins, a conserved BH4 motif was recently 
observed (Kvansakul et al., 2008). Following activation, Bak and Bax undergo homo-
oligomerization thus promoting MOMP by formation of proteolipid pores within the OMM. 
The BH3-only proteins, sharing the homology with Bcl-2 in the BH3 region only, are divided 
based on their ability to interact either with the antiapoptotic members or with both the 
antiapoptotic and the effector proteins. BH3-only proteins such as Bad (Bcl-2 antagonist of 
cell death) and Noxa are referred to as ‘‘sensitizer’’ and/or ‘‘derepressor” and interact, 
through the BH3 region, only with the antiapoptotic members of the family. The BH3-only 
proteins that are referred as ‘‘direct activators’’, such as Bid (Bcl-2-interacting domain death 
agonist) and BIM (Bcl-2-interacting mediator of cell death), can interact with the 
antiapoptotic repertoire as well as with the effectors, and can directly induce Bak and Bax 
oligomerization and MOMP (Chipuk et. al, 2010). Correct interactions between pro and 
antiapoptotic Bcl-2 family members are crucial for the normal activation of the intrinsic 
pathway and apoptosis regulation.  
Resistance to apoptosis, frequently caused by overexpression of antiapoptotic proteins, is a 
common feature of cancer. In fact, it has been demonstrated that deficiency in apoptosis is 
one of the key hallmarks of cancer (Hanahan & Weinberg, 2000). High levels of Bcl-2 
expression have been found in many cancers, such as follicular lymphoma (Gaulard et al., 
1992), chronic lymphocytic leukemia (CLL) (Schena et al., 1992), AML (Andreeff et al., 1999), 
MM (Harada et al., 1998), small cell lung cancer (Ben-Ezra et al., 1994) and melanoma (Leiter 
et al., 2000). Elevated expression of the antiapoptotic proteins Bcl-2, Bcl-xL and Mcl-1 has 
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been reported also in ALL cell lines and primary samples (Campana et al., 1993; Coustan-
Smith et al. 1996; Del Gaizo Moore et al., 2008; Hogarth & Hall, 1999). In particular, several 
studies have shown that higher Bcl-2 levels are associated with improved ability of ALL 
cells to survive under very unfavorable culture conditions, such as the absence of stromal-
derived growth factors. Therefore, Bcl-2 overexpression may contribute to leukemogenesis 
and influences the survival ability of leukemic lymphoblasts. Moreover, Bcl-2 
overexpression may provide an explanation of the ability of leukemic lymphoblasts to 
expand outside the bone marrow microenvironment (Campana et al., 1993; Coustan-Smith 
et al., 1996). To test the hypothesis that the apoptotic defects are essential for tumor 
maintenance, Letai et al. (2004) have generated a transgenic mouse model expressing a 
conditional Bcl-2 gene and constitutive c-myc that develop lymphoblastic leukemia. They 
have shown that Bcl-2 elimination yielded rapid loss of leukemic cells and significantly 
prolonged mouse survival, formally validating Bcl-2 as a rational target for a targeted cancer 
therapy (Letai et al., 2004). Furthermore, high Bcl-2 levels are observed also in ALL 
characterized by t(4;11) (Robinson et al., 2008). It has been demonstrated that the 
equilibrium in the formation of Bcl-2:Bax heterodimers (suppressors of death) and Bax:Bax 
homodimers (activators of death) appears to be central in the molecular regulation of 
apoptosis (Coustan-Smith et al, 1996). In fact, high Bax expression alone was shown to be 
associated with an increased probability of relapse (Hogarth & Hall, 1999) and both Bax 
expression levels and the Bax/Bcl-2 ratio are significantly lower in samples at relapse, as 
compared with samples at initial diagnosis (Prokop et al., 2000). Kaufman et al. (1998) have 
shown that Mcl-1 is highly expressed in ALL at relapse, resulting two times higher as 
compared to pre-treatment levels. Further studies have correlated increased expression of 
Bcl-2 antiapoptotic family members to increased tumor cell survival and drug resistance in 
vitro and in vivo (Del Gaizo Moore et al., 2008). Holleman et al. (2004) observed 
overexpression of the antiapoptosis gene Mcl-1 in prednisolone-resistant ALL. Wei et al. 
(2006) have shown that Mcl-1 is also involved in glucocortocoid (GC) resistance in ALL. In 
this report, by combining bioinformatic analyses of gene expression profiles of childood 
ALL (classified as GC-sensitive/resistant by ex vivo testing) with functional data obtained 
from experimental systems, they identified Mcl-1 as the key member of the antiapoptotic 
Bcl-2 family, responsible for GC resistance (Wei et al., 2006). These observations suggest that 
inhibition of the antiapoptotic/pro-survival members of Bcl-2 family proteins may represent 
an attractive approach for the treatment of ALL.  
Several strategies have been developed to inhibit the activity of the Bcl-2 family of proteins, 
including antisense oligonucleotides, peptides derived from the BH3 domain, and small 
molecule antagonists. While clinical studies with peptides rarely progress to late-stage trials, 
because of poor pharmacological properties (Lessene et al., 2008), small molecules proved 
more effective. Small molecule inhibitors are designed to compete with activator and 
sensitizer molecules for the same binding site on Bcl-2 family members (the BH3 domain) 
and consequently they are referred to as BH3 mimetics (Richardson & Kaye, 2008). Several 
molecules has been developed as BH3 mimetics; one the most attractive is ABT-737 
(Oltersdorf et al. 2005) and its orally bioactive analog ABT-263. Apoptosis induced by ABT-
737 is dependent on Bax and Bak (Van Delft et al., 2006) suggesting that its primary 
mechanism of action is through the regulation of the intrinsic apoptosis pathway. ABT-737 
is a Bcl-2/Bcl-xL inhibitor that specifically binds the hydrophobic groove that normally 
serves as a binding site for the BH3 domain of activators and sensitizers. ABT-737 binds  
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Fig. 2. The Bcl-2 family of proteins (TM: transmembrane domain). 
potently Bcl-2, Bcl-xL and Bcl-w, instead only weakly Bfl/A1 or Mcl-1. In fact, Mcl-1 
overexpression is reported to be one of the principal factors that may confer resistance to  
ABT-737 (Konopleva et al., 2006). Pre-clinical studies have shown that ABT-737 displays a 
potent growth-inhibitory activity in ALL. In particular we and others have evaluated 
preclinical activity of ABT-737 on a panel of ALL cell lines and primary cells obtained from 
ALL patients, observing a strong increase in apoptosis induction (Del Gaizo Moore et al., 
2008; Tafuri et al., 2007). Furthermore, we employed a combined preclinical strategy to 
overcome the ABT-737 resistance in ALL cells using the mTOR inhibitor CCI-779. We 
observed synergistic effects on apoptosis induction between ABT-737 and CCI-779 in both 
ALL cell lines and in a proportion of primary cells (Iacovelli et al., 2010). Other studies 
employing ABT-737 in combination with L-asparaginase, topotecan, vincristine and 
etoposide have shown increased antileukemic effects against drug-resistant ALL xenografts 
models (High et al., 2010). Since ABT-737 was not orally bio-available, the oral analog ABT-
263, capable of initiate apoptosis following 2 hours from administration, has been 
developed. The dosing flexibility of ABT-263 accomplished by its oral efficacy prompt the 
clinical investigation of this molecule, both as a single agent and in combination. The ABT-
263 is currently employed in phase I clinical trials in both hematological and solid tumors 
(Gandhi et al., 2011; Wilson et al., 2010). GX15-070 (Obatoclax) is another BH3 mimetic, 
which binds to Bcl-2, Bcl-xL and Mcl-1 with comparable affinity (Lessene et al., 2008); for 
this reason, Obatoclax may potentially overcome resistance conferred by high levels of Mcl-
1, inhibiting the interaction between Bak and Mcl-1 (Trudel et al., 2007). Several reports have 
shown that increased Mcl-1 expression is associated with GC resistance (Holleman et al., 
2004; Stam et al., 2010) and it has been demonstrated that Obatoclax treatment can re-
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sensitizes GC-resistant ALL cells (Bonapace et al., 2010). Other results suggest that 
Obatoclax could be useful as a therapeutic agent against ALL and that the activity and/or 
the expression of antiapoptotic proteins could be used as a biomarker to determine the 
appropriate treatment strategy for ALL patients (Heidari et al., 2010). In particular, 
Bonapace et al have shown that Obatoclax can overcome the resistance to GC through rapid 
activation of autophagy-dependent necroptosis, which was able to bypass the apoptotic block 
in the mitochondrion. This effect required Obatoclax-mediated dissociation of Beclin-1 from 
Mcl-1 and was associated with inhibition of mTOR activity (Bonapace et al., 2010). Autophagy 
is a cell death mechanism distinct from apoptosis, also called type 2, non-apoptotic cell death. 
Autophagy is characterized by the inclusion of cytoplasmic material into vacuoles, leading to 
degradation mediated by lysosomal enzymes (Klionsky, 2007). Beclin-1 is a novel BH3 domain 
protein involved in autophagy, which plays an essential role in the activation of this cell death 
process. Beclin-1 can be activated or inactivated by its interaction with the pro or antiapoptotic 
members of the Bcl-2 family, respectively, through the BH3 domain. Thus, the cells can 
regulate autophagy by targeting Beclin-1 through Bcl-2 family members (Levine et al., 2008). 
Small molecules, such as ABT-737 and Obatoclax, by acting as BH3 inhibitors, can overcome 
resistance mediated by Bcl-2 antiapoptotic members, thereby restoring the cellular ability to 
induce autophagy (Bonapace et al., 2010; Levine et al., 2008). 
The use of the BH3 mimetics, alone or in combination with other inhibitors or 
chemotherapy, can be of great importance in customizing an individual patient’s therapy 
especially in cases in which chemotherapy alone is not able to decrease tumor burden. 
5. Epigenetic silencing 
The term “epigenetic” is generally referred to heritable changes in gene expression not 
caused by alterations in the DNA coding sequences. Epigenetic changes such as DNA 
methylation or histone modifications work in concert with each other to regulate gene 
expression in normal mammalian development (Baylin & Ohm 2006). However, it is now 
evident that epigenetic modifications considerably contribute to development and 
progression of carcinogenesis in general, and of leukemogenesis in particular (Baylin & 
Ohm, 2006; Chen et al., 2010). 
5.1 DNA methylation 
DNA methylation is mediated by a family of enzymes, DNA methyltransferases 
(DNMTs), which catalyze the covalent addition of a methyl group at the 5’ carbon of 
cytosine residues that precede guanosine (CpG) islands (Herman & Baylin, 2003). The 
resulting 5-methylcytosines protrude into the major groove of DNA, inhibiting gene 
transcription. 
In mammalian cells, 5-methylcytosine is found in approximately 5% of the whole genome. 
Compared to normal cells, cancer cells display aberrant methylation of cytosine residues 
both in gene promoters or coding regions, leading to a transcriptional silencing of tumor 
suppressor gene. Cyclin-dependent kinase inhibitors, such as CDKN2B, which encodes the 
tumor suppressor p15 (INK4B), and CDKN2A, which encodes the tumor suppressors p16 
(INK4A) are, among other genes, frequently methylated in their promoter regions (Garcia-
Manero et al., 2009; Roman-Gomez et al., 2004). This epigenetic modification has been 
described also in ALL. Results obtained by Roman-Gomez at al. (2004) in 251 consecutive 
ALL patients demonstrated that promoter hypermethylation of multiple genes is a common 
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phenomenon in ALL and is a strong independent prognostic factor in predicting the clinical 
outcome of ALL patients. In particular, they observed that methylation in ALL cells mostly 
participate to inactivation of genes involved in: 1) cell growth regulation by controlling 
directly (p15, p16 and p57) or indirectly (p73, PTEN, NES-1) cell cycle check-points; 2) 
apoptosis inhibition (p14, TMS1, APAF-1 and DAPK); 3) cell adhesion (some members of 
cadherin family). However, the relationship between aberrant DNA methylation and 
protein expression of tumor suppression genes has not yet been extensively evaluated in 
adult ALL series. Bueso-Ramos et al. (2005) showed that methylation of more than one gene 
of the pathway composed of p73, p15 and p57 was associated with a worse outcome of adult 
ALL patients. However, lack of association was reported between p73 protein expression and 
clinical-biologic characteristic. We analyzed the promoter methylation status of p73, p21, p15 
and p16, evaluating in addition the p21, p15 and p16 protein expression, in primary cells from 
newly diagnosed adult ALL patients, uniformly treated according to the GIMEMA LAL2000 
protocol. Our results indicate that in vivo p15 and p21 protein expression plays an unfavorable 
prognostic role in adult ALL patients independently of the p73, p21, p15 and p16 gene 
promoter methylation status (De Cave et al. 2007). Data reported by Yang et al. (2009) 
demonstrated that detection of epigenetic alterations allows the identification of ALL patients 
with poor prognosis within the standard-risk group. More recently, Milani L et al. (2010), 
analyzing the methylation patterns of CpG sites in 416 genes, have found a striking difference 
in the methylation patterns within a large number of samples from ALL patients. Notably, 
they observed a correlation between the methylation level and clinical outcome within major 
subgroups of ALL patients, identifying 20 genes with DNA methylation levels capable to 
predict leukemia relapse. These observations suggest that methylation analysis should be 
explored to identify ALL patients at different risk. 
5.2 Histone modifications 
Structural studies have demonstrated that histones easily undergo post-translational 
modifications in their long amino-teminal tails that project outward from the nucleosome. 
These tail modifications, which include acetylation, methylation, phosphorylation, 
ubiquitination, ADP-ribosylation, are involved in several biological processes related to the 
chromatin structure, i.e. gene regulation, DNA repair, DNA replication, chromatin 
condensation etc. (Bhaumik et al., 2007). 
Histone acetylation acts in concert with DNA methylation to regulate gene expression. 
Several data have demonstrated that histone acetylation, catalysed by histone 
acetyltransferases (HATs), is involved in maintaining chromatin structure in a 
transcriptionally active form (Chen et al., 2010). In contrast, histone deacetylation (HDAC), 
removing acetyl groups from histone tails, permits the histones to wrap more tightly around 
the DNA and thus maintains genes inactivated and silenced. High level of HDAC 
expression is a common finding in cancer cells (Moreno et al, 2010) and accounts for the 
aberrant expression and activity of numerous proteins involved in proliferation, 
differentiation, apoptosis, adhesion and migration (Lane & Chabner, 2009). A high 
expression of HDAC has also been described in hematological malignancies, particularly in 
lymphomas (Marquard et al, 2009) and in AML (Cimino et al, 2006). Thus far, very few data 
are available about HDAC expression in ALL. 
In a recent study conducted by Moreno and colleagues (2010) on childhood ALL samples, 
the authors observed a differential HDACs expression between clinical samples. 
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Particularly, they found a higher expression of HDAC1 and HDAC4 and a lower expression 
of HDAC5 in T-ALL. Moreover, they reported that higher expression of HDAC7 and 
HDAC9 is associated with poor prognosis both in the overall group of childhood ALL and 
in B-lineage CD10-positive cases suggesting the use of HDAC inhibitors as a promising 
therapeutic intervention for the treatment of refractory childhood ALL. 
5.3 Epigenetic therapy 
Because of the key role of epigenetic modifications in the pathogenesis of cancer, 
pharmacological agents that target components of the epigenetic machinery are become 
promising elements of the therapeutic arsenal for cancer treatment. 
Several data have indicated that DNA methyltransferase inhibitors (DNMTi), such as 
azacitidine, decitabine, and other derivative, are able to restore tumor suppressor gene 
expression and exert antitumor effects in vitro and in vivo by inhibiting hypermethylation 
(Chen et al., 2010). Clinical studies have clearly demonstrated that DNMTi, used alone or in 
combination, may convey clinical benefit to patients with hematological malignancies, 
especially myelodysplastic syndrome and AML. In contrast, the application of this therapeutic 
strategy to ALL patients is so far limited. Recent data reported by Schafer et al. (2010) have 
demonstrated that MLL rearranged (MLL-r) infant ALL samples, compared with other 
childhood leukemias and normal controls, are characterized by promoter hypermethylation of 
several genes. Notably, they showed that decitabine preferentially kills MLL-r lymphoblastic 
leukemia cell lines and also that this response correlates with the upregulation of several of the 
identified silenced genes, suggesting predictable efficacy of demethylating agents in this 
category of infant ALL that is reported as the most aggressive type of childhood leukemia. 
More recently, studying the same category of MLL-r infant ALL patients, Stumpel et al. (2011) 
observed that in samples from infant ALL patients carrying the t(4;11), eleven miRNAs were 
downregulated as a consequence of hypermethylation and seven of these were re-activated 
after exposure to a demethylating agent, thus providing additional evidence that 
demethylating agents should be tested for their efficacy in MLL-r infant ALL patients.   
HDAC inhibitors (HDAC-Is) are a class of agents with the capacity to induce acetylation of 
histone and non-histone proteins (Lee et al. 2010). These molecules have been intensively 
investigated in preclinical models as well as in clinical trials for a variety of malignancies, 
because of their ability to inhibit proliferation, induce differentiation, and cause apoptosis in 
tumor cells (Bolden et al. 2006; Lee et al., 2010). Since only a portion of patients has a 
therapeutic response, a very important issue is the need to identify markers of potential 
response or resistance to HDAC-Is. Currently, there is great interest in the HDAC-Is field, as 
several new and more effective compounds are being developed and entering clinical trials. 
In ALL, HDAC-Is have been used only for in vitro studies. It has been demonstrated that 
HDAC-Is induce apoptosis in ALL cell lines (Moreno et al., 2010; Romanski et al., 2004), 
including those resistant to glucocorticoid, and in ex vivo-cultured samples. Our preliminary 
results in vitro show that novel HDAC-Is are potent growth inhibitors and inducers of 
apoptosis in human leukemia cells, including ALL cell lines, and suggest their potential 
therapeutic use for patients with leukemias. 
Future research will definitely suggest additional therapeutic targets regulating epigenetic 
pathways and continued clinical trials with demethylating agents and HDAC inhibitors, 
alone or in combination, will undoubtedly provide further advance in the treatment of 
hematological malignancies, including ALL cases. 
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6. Bone marrow microenvironment 
Bone marrow (BM) is a complex and dynamic network of hematopoietic and stromal cells, 
blood vessels, proteins and others microenvironmental factors, such as growth factors and 
cytokines that compose the extracellular matrix (ECM) (Ayala et al., 2009). The interaction 
between hematopoietic and stromal or mesenchymal cells, as well as between cellular and 
soluble components of BM microenvironment, sustains normal hematopoiesis by promoting 
cell growth, regulating differentiation, and importantly maintaining a pool of 
undifferentiated pluripotent and long-lived stem cells (Ayala et al., 2009; Rizo et al., 2006). 
The BM microenvironment is critical for B-cell lymphopoiesis.  
Similar to normal hematopoiesis, the survival and growth of leukemic cells largely depend 
on the support provided by the BM microenvironment, which also contributes to blunt the 
effects of chemotherapy and provides a sanctuary for minimal residual disease. Notably, 
several data have demonstrated the key role of BM microenvironment in supporting the 
survival of leukemic stem cells (LCS), also known as “leukemia initiating cells”, i.e. the 
subpopulation of cells within a tumor that are long lived, has the potential to self-renew, can 
generate the original tumor in xenograft models (Konopleva & Jordan, 2011; Moore & Lyle, 
2011) and are therefore thought to be the cause of relapse in patients treated with traditional 
drugs. The emerging concept of LSC niche as a dynamic entity in which interactions 
between the LCS and its microenvironment take place are now becoming a hot topic 
highlighting the relevance of BM microenvironment for leukemia initiation, progression and 
drug resistance and opening up opportunities for therapeutic intervention (Ayala et al., 
2009; Rizo et al., 2006).  
The mechanism by which the BM stroma modulates growth, progression and response to 
chemotherapy of ALL cells is not fully elucidated. In vitro studies of primary ALL cells 
usually demonstrate a large amount of spontaneous ALL cell apoptosis which could be 
reduced by co-culturing them with BM stromal cells, increasing survival and proliferation 
and blunting the cytotoxic effects of chemotherapeutic agents (Brown et al., 2008). There are 
evidences that interactions of ALL cells with BM stroma are mediated by different members 
of the integrin family of proteins, constitutively expressed on leukemic cells (LFA-1 on T-
ALL and VLA-4 on B-ALL), with their respective ligands exposed on the surface of BM 
stromal cells or secreted in the ECM (fibronectin) (Ayala et al., 2009; Tabe et al., 2007). These 
interactions lead to the activation of tyrosine kinases, and consequently of downstream 
pathways which regulate cell growth, survival, adhesion, migration, angiogenesis, apoptosis 
and autophagy (Tabe et al., 2007; Veiga et al., 2006). The PI3K/PTEN/AKT/mTOR cascade 
is a critical pathway in stromal/leukemic cells interactions mediated by integrins, 
chemokines (such as CXCR4/CXCL12), angiogenic factors and interleukins (Konopleva & 
Jordan, 2011). 
It is well known that interleukins, such as IL-7 and IL-3, have a critical role in regulation 
proliferation and survival of T- (Scupoli et al., 2007) and B-ALL (Juarez et al., 2007) cells by 
activating stroma interactions. Addition of IL-7 to co-cultures of BM stromal cells and ALL 
cells has been reported to increase ALL cell survival through phosphorylation of AKT, 
ERK1/2, and p38 (Juarez et al., 2007). Crosstalk between BM microenvironment and 
leukemic cells has also been demonstrated by upregulation of IL-8 in leukemic cells 
promoted by CXCR4/CXCL12-induced activation of the NF-kB and JNK/AP-1 pathways 
(Scupoli et al., 2008). High levels of IL-8 could in turn enhance angiogenesis in the BM 
microenvironment and indirectly sustain tumor growth (Scupoli et al., 2008). Ultimately, it 
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has been demonstrated that CXCR4 has a role in homing and migration of ALL blasts in BM 
and in other organs (Konopleva & Jordan, 2011; Sipkins et al., 2005). 
Increased neovascularization, which effectively contributes to growth and progression of 
cancer, has been described in ALL as a result of autocrine and/or paracrine loops of the 
main proangiogenic mediators (bFGF, VEGF and angiopoietin) promoted by BM 
stroma/leukemic blast interactions (Ayala et al., 2009). Beside marked neovascularisation, 
extensive endothelial cell proliferation represents one of the most pronounced 
microenvironmental changes observed in BM of ALL patients (Veiga et al., 2006). Several 
studies have demonstrated the existence of a crosstalk between the endothelium and 
leukemic cells, in which leukemia cells stimulate BM endothelium and promote de novo 
angiogenesis and neovascularisation, while BM endothelium promoted leukemia cell 
survival through modulation of antiapoptotic bcl-2 family members (Veiga et al., 2006). 
Another study by Aref et al. (2007) described in B-ALL an abnormal expression of matrix 
metalloproteinases (MMP), which is a further class of angiogenesis and tumor progression 
regulators produced by both stromal and leukemic cells (Aref et al., 2007) 
A further interesting aspect related to BM microenvironment and leukemia cells interactions 
regards the role of BM microenvironment on lineage commitment and differentiation. 
Several studies have indeed demonstrated that BM microenvironment can drive lineage-
specific differentiation in leukemia by modulating different cytokines and other soluble 
components (Kankuri et al., 2008; Wei et al., 2008). In an elegant study performed on a 
human MLL-AF9 leukemia model transplanted into immunodeficient mice, Wei J et al. 
(2008) showed that ALL, AML or mixed-lineage leukemia were generated by altering the 
cytokine milieu of human CD34+ cells expressing MLL-AF9, thus demonstrating the 
importance of the microenvironment in driving leukemia phenotype. 
Finally, a translationally relevant concept is that the BM microenvironment can also regulate 
the response of leukemic cells to chemotherapy through a variety of mechanisms. According 
to the evidences described before, BM microenvironment mainly contributes to protection of 
leukemic cells from drug effects participating in induction of a chemo-resistant phenotype. 
For instance, high levels of asparagine synthetase produced by BM-derived mesenchymal 
cells have been demonstrated as one of the mechanisms participating in the resistance to 
asparaginase in ALL samples (Iwamoto et al., 2007). Moreover, it has been reported that IL-7 
and TSLP protect ALL cells in vitro from MTI-induced effects suggesting that stromal cell-
derived cytokines can contribute to MTI resistance (Brown et al, 2007). 
In conclusion, these evidences demonstrate the importance of interaction between BM 
stromal cells and ALL blasts and chemoresistance, the role of BM microenvironment and 
ultimately the potential of therapeutic approaches based on disrupting this interaction in 
ALL patients. 
7. From personalized proteomic profiles to personalized medicine in ALL 
In order to tailor a personalized therapy, it is mandatory that research is aimed at 
identifying specific targets on the malignant cells in order to dissect groups of patients with 
different risks and to develop new drugs with selective activity against the tumor cell. The 
characterization of molecular profiles of cancer cells, compared to their normal counterparts, 
requires the continuous development of comprehensive molecular analysis technologies. It 
is particularly crucial to implement and support the development of novel technologies that 
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allow high-throughput analysis of genetic alterations, expression of genome products and 
monitoring the STP in cancers. Although a complete description of these new technologies is 
beyond the scope of this chapter, some observations regarding the most promising 
techniques that may allow to further decipher the molecular profile of leukemia samples at 
the post-translational level are herein reported. 
Understanding cancer cell physiopathology at the protein level requires the development of 
reliable proteomics. In addition, profiling and classification of several components of 
multiple aberrant STP would be expected to accurately predict disease behavior and 
prognosis. Moreover, the challenge of translating proteomic pathway profiling to the 
bedside would require a technique capable of efficiently processing small numbers of cancer 
cells by routinely assessing multiple STP simultaneously. Traditional protein assay 
techniques like Western blotting (WB) and ELISA assay can assess the level of protein 
phosphorylation. WB can evaluate a limited number of proteins and samples in a semi-
quantitative way requiring large amounts of cellular material. The ELISA assay gives 
quantitative information but is extremely expensive. Further attempts have been made by 
MALDI-TOF (matrix assisted laser desorption/ionization-time of flight) and by two-
dimensional gel-electrophoresis. However, both methods cannot be performed on a large 
scale on clinical samples and, more importantly, they require large numbers of cells 
(Petricoin et al., 2005) 
The Reverse Phase Protein Arrays (RPPA) is an emerging, sensitive, high-throughput 
technology that allows profiling the STP working state of large clinical populations, 
examining the functional proteomic profile of each sample. By quantitative analysis of 
minuscule amounts of proteins (nanoliters of protein lysates equivalent to picograms of 
proteins), RPPA permits the measurements of proteins and their corresponding 
phosphoproteins by using high-quality monoclonal antibodies. At the same time, cell lysates 
collected from hundred of samples are spotted on a single slide, making this methods highly 
effective in retrospective clinical sample analysis or in prospectively collected sets of 
samples. Compared to WB, which uses proteins from 5 X 105 cells for each antibody analysis, 
RPPA requires proteins from only 5.000-20.000 cells per sample preparation and a protein 
amount equivalent to 200 cells is spotted per slide for a single antibody. Therefore, 20.000 
cells would be sufficient to analyze 100 different protein targets and the amount of material 
previously used for single WB will be now used for 2500 antibodies by RPPA. This will thus 
be particularly useful for protein detection of rare populations (stem cells, residual cells 
surviving after chemotherapy) (Kornblau et al., 2009). RPPA has been successfully applied 
in a number of basic and clinical studies (Accordi et al., 2010; Kornblau et al., 2009; Petricoin 
et al., 2007). In a very recent study published by Accordi et al. (2011) the RPPA technique 
was applied to analyze the activation/expression status of 92 key signaling proteins in 118 
pediatric B-ALL patients. The authors found an aberrant activation and/or increased 
expression of several pathways involved in cell proliferation (such as Bcl-2 
hyperphosphorylation, LCK and cyclin E up-modulation) in patients with poor prognosis. 
Our group has applied RPPA on adult and pediatric ALL patients, identifying B- and T-
lineage ALL by the proteomic profile, showing in addition a prognostic role of cell cycle and 
apoptotic molecule over-expression in ALL patients (Tafuri et al. unpublished results).   
Alternatively to the phospho-proteomic array technology, it is possible to perform a “single-
cell proteomic” analysis by using flow cytometry (Irish et al., 2006). The powerful multi-
parametric single cell analysis platforms nowadays available allow simultaneously 
determining and quantifying the active or inactive state of multiple signaling components in 
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individual cancer cells using fluorophore-conjugated antibodies. A “single-cell signaling 
signature” can be obtained for each cell in a mixed population and compared either with 
other features on the same cell or with normal cells present in patient samples. Therefore, 
single-cell analysis by flow cytometry is particularly useful to analyze samples for rare (HCS 
or LCS) and/or heterogeneous cell type populations. Recent data published by Gibbs et al 
(2011) demonstrated the biochemical and functional heterogeneity of human HSCs by using 
single-cell phospho-specific flow cytometric analysis. Analyzing the response profile of 
human HSCs to a broad range of hematopoietic cytokines the authors demonstrated that the 
HSC compartment is composed of biochemically distinct subsets, and that cellular 
proliferation can be directly regulated by G-CSF. 
8. Concluding remarks 
Comprehensive molecular analysis of cancer over the past decades has clearly shown that 
most malignancies are composed of several molecular subgroups, each defined by specific 
genetic/epigenetic alterations and with different prognosis. In the past years, diagnostic and 
prognostic achievements obtained through molecular genetics have improved patient 
follow-up, addressing treatment choice and anticipating treatment failure. In the post-
genomic era, the translational approach to diseases, especially to hematologic and solid 
malignancies, must exceed including new tools for dissecting the functional proteomic and 
metabolomic profiling.  Future clinical technologies may expand studies on protein arrays 
helping to define in large clinical population the functional proteomic profile at steady-state; 
this approach may lead to the identification of aberrant molecular target(s), possibly guiding 
the choice of specific molecular therapies, on one hand, and leading to elucidate of post-
treatment changes, on the other hand, with the overall objective of improving the strategies 
currently employed to counteract leukemia chemo- and targeted drug-resistance. The 
ongoing new challenge will be to manage the enormous amount of data often produced by 
these technologies, approaching statistical methods that may accurately identify the most 
important clinical and biological variables.  
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